[February 18, 2014] |
 |
Novimmune Announces Closing of CHF 60 Million Financing
GENEVA --(Business Wire)--
Novimmune
SA announced that it has closed a Series B financing for CHF 60
million ($66 million). London-based Rosetta Capital Limited led the
round with participation of new private investors as well as existing
investors.
Dr. Jonathan Hepple, Partner at Rosetta, has joined Novimmune's Board of
Directors. Dr. Hepple brings more than 15 years' investment experience
in the life science industry. He is a co-founder of Rosetta Capital, a
London-based advisory and venture capital firm focused on the life
sciences sector.
"We welcome Rosetta as a new investor in Novimmune and look forward to
working with Jonathan as a new member of our Board," commented Jack
Barbut, CEO of Novimmune. "His experience across orphan disease and
protein engineering companies, and in the investment sector, nicely
complements Novimmune's other Board members' perspectives."
"This is an exciting time to become involved with Novimmune," commented
Dr. Hepple. "The Company is advancing valuable new medicines by pursuing
a three-pillar strategy - NI-0501 is a clinical-stage drug candidate for
a life threatening disease, which Novimmune intends to develop and
commercialize with its own resources, setting the basis for a high-value
orphan business. NI-0101, a first in class clinical-stage anti-TLR4
antibody, addresses broad market opportunities that may enable the
Company to establish a major strategic partnership. Finally, Novimmune's
unique kappa/lambda body™ bispecific drug platform, particularly its
application to selectively inhibit CD47 on cancer cells, holds promise
to benefit a broad range of cancer patients."
About Novimmune
Novimmune is focused on the creation of medicines to serve patients in
need. In addition to entering partnerships to exploit large market
opportunities and its next-generation antibody drug platform, the
Company plans to bring medicines to market for orphan disease
applications.
For further information visit our website at www.novimmune.com

[ Back To TMCnet.com's Homepage ]
|